Ryan Nelson1, Chuanhong Liao, Alessandro Fichera, David T Rubin, Joel Pekow. 1. *Section of Gastroenterology, Hepatology, and Nutrition, †Department of Health Studies, the University of Chicago Medicine, Chicago, Illinois; and ‡Department of Surgery, University of Washington Medicine, Seattle, Washington.
Abstract
BACKGROUND: Cyclosporine and infliximab (IFX) are effective medical therapies for inducing remission in patients with steroid-refractory ulcerative colitis (UC). Patients with acute severe disease who do not respond to these therapies require colectomy, however, the risk of postoperative complications in such patients is not known. Analyzing patients with acute severe UC, we compared the incidence of postoperative complications in patients who failed rescue therapy with cyclosporine or IFX with that in patients who received intravenous (IV) corticosteroids alone. METHODS: We performed a retrospective cohort study of UC patients who underwent colectomy after inpatient treatment with cyclosporine plus IV corticosteroids (CsA+IVS), infliximab plus IV corticosteroids (IFX+IVS), or IV corticosteroids alone (IVS) at the University of Chicago Hospitals from October 1, 2006 to October 1, 2012. Primary endpoints were infectious, noninfectious, and total complications occurring within 30 days of colectomy. RESULTS: Of 78 patients, 19 were treated with CsA+IVS, 24 with IFX+IVS, 4 with both CsA and IFX+IVS, and 31 with IVS alone. Patients treated with rescue therapy plus IVS had no difference in total postoperative complications compared with those receiving IVS alone (CsA+IVS: relative risk (RR) = 0.63, 95% confidence interval (CI), 0.33-1.23; IFX+IVS: RR = 0.65, 95% CI, 0.36-1.17). There remained no difference in postoperative complications between the rescue therapy and IVS alone groups when subcategorizing overall complications into infectious (CsA+IVS: RR = 0.54, 95% CI, 0.17-1.76; IFX+IVS: RR = 0.86, 95% CI, 0.36-2.09) and noninfectious (CsA+IVS: RR = 0.88, 95% CI, 0.43-1.80; IFX+IVS: RR = 0.40, 95% CI, 0.15-1.07) causes. CONCLUSIONS: Cyclosporine and IFX are not associated with an increased risk for postoperative complications in patients hospitalized for severe UC refractory to corticosteroids.
BACKGROUND:Cyclosporine and infliximab (IFX) are effective medical therapies for inducing remission in patients with steroid-refractory ulcerative colitis (UC). Patients with acute severe disease who do not respond to these therapies require colectomy, however, the risk of postoperative complications in such patients is not known. Analyzing patients with acute severe UC, we compared the incidence of postoperative complications in patients who failed rescue therapy with cyclosporine or IFX with that in patients who received intravenous (IV) corticosteroids alone. METHODS: We performed a retrospective cohort study of UC patients who underwent colectomy after inpatient treatment with cyclosporine plus IV corticosteroids (CsA+IVS), infliximab plus IV corticosteroids (IFX+IVS), or IV corticosteroids alone (IVS) at the University of Chicago Hospitals from October 1, 2006 to October 1, 2012. Primary endpoints were infectious, noninfectious, and total complications occurring within 30 days of colectomy. RESULTS: Of 78 patients, 19 were treated with CsA+IVS, 24 with IFX+IVS, 4 with both CsA and IFX+IVS, and 31 with IVS alone. Patients treated with rescue therapy plus IVS had no difference in total postoperative complications compared with those receiving IVS alone (CsA+IVS: relative risk (RR) = 0.63, 95% confidence interval (CI), 0.33-1.23; IFX+IVS: RR = 0.65, 95% CI, 0.36-1.17). There remained no difference in postoperative complications between the rescue therapy and IVS alone groups when subcategorizing overall complications into infectious (CsA+IVS: RR = 0.54, 95% CI, 0.17-1.76; IFX+IVS: RR = 0.86, 95% CI, 0.36-2.09) and noninfectious (CsA+IVS: RR = 0.88, 95% CI, 0.43-1.80; IFX+IVS: RR = 0.40, 95% CI, 0.15-1.07) causes. CONCLUSIONS:Cyclosporine and IFX are not associated with an increased risk for postoperative complications in patients hospitalized for severe UC refractory to corticosteroids.
Authors: Matthias Jürgens; Rüdiger P Laubender; Franziska Hartl; Maria Weidinger; Julia Seiderer; Johanna Wagner; Martin Wetzke; Florian Beigel; Simone Pfennig; Johannes Stallhofer; Fabian Schnitzler; Cornelia Tillack; Peter Lohse; Burkhard Göke; Jürgen Glas; Thomas Ochsenkühn; Stephan Brand Journal: Am J Gastroenterol Date: 2010-03-02 Impact factor: 10.864
Authors: B M Nørgård; J Nielsen; N Qvist; K O Gradel; O B S de Muckadell; J Kjeldsen Journal: Aliment Pharmacol Ther Date: 2012-04-16 Impact factor: 8.171
Authors: Mats Sjöberg; Andrea Walch; Mina Meshkat; Anders Gustavsson; Gunnar Järnerot; Harald Vogelsang; Erik Hertervig; Gottfried Novacek; Ingalill Friis-Liby; Lars Blomquist; Sieglinde Angelberger; Per Karlen; Christer Grännö; Mogens Vilien; Magnus Ström; Hans Verbaan; Per M Hellström; Clemens Dejaco; Anders Magnuson; Jonas Halfvarson; Walter Reinisch; Curt Tysk Journal: Inflamm Bowel Dis Date: 2011-03-15 Impact factor: 5.325
Authors: Melanie L Gainsbury; Daniel I Chu; Lauren A Howard; Jennifer A Coukos; Francis A Farraye; Arthur F Stucchi; James M Becker Journal: J Gastrointest Surg Date: 2011-01-19 Impact factor: 3.452
Authors: Neeraj Narula; John K Marshall; Jean-Frederic Colombel; Grigorios I Leontiadis; John G Williams; Zack Muqtadir; Walter Reinisch Journal: Am J Gastroenterol Date: 2016-02-09 Impact factor: 10.864
Authors: Audrey S Kulaylat; Afif N Kulaylat; Eric W Schaefer; Andrew Tinsley; Emmanuelle Williams; Walter Koltun; Christopher S Hollenbeak; Evangelos Messaris Journal: JAMA Surg Date: 2017-08-16 Impact factor: 14.766
Authors: Jurij Hanzel; Ahmed Almradi; Alexandra C Istl; Mei Lucy Yang; Katherine A Fleshner; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Siddharth Singh; Vipul Jairath Journal: Dig Dis Sci Date: 2021-02-26 Impact factor: 3.199
Authors: M P Martínez-Montiel; B Casis-Herce; G J Gómez-Gómez; A Masedo-González; C Yela-San Bernardino; C Piedracoba; G Castellano-Tortajada Journal: Clin Exp Gastroenterol Date: 2015-08-17